Eli Lilly & Co. - LLY STOCK NEWS

Eli Lilly and Company (NYSE: LLY) will participate in Bernstein's Second Annual Operational Decisions Conference on Thursday, Nov. 4, 2021. Key executives including Jake Van Naarden, Mark Mintun, and Jamie Croaning will engage in a virtual fireside chat at 12:30 p.m. Eastern time. Investors can access a live audio webcast via Lilly's Investor website, with a replay available for 90 days. Lilly aims to improve global health care through innovative medicines and community support, continuing a mission established over a century ago. For more details, visit www.lilly.com.

On October 28, 2021, Eli Lilly announced the publication of overall survival data from the Phase 3 monarchE study of Verzenio (abemaciclib) in the Annals of Oncology. This study explores the effectiveness of Verzenio in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. Notably, the FDA approved Verzenio in combination with endocrine therapy for specific patient populations earlier in the month. Although the overall survival data are still immature, they are pivotal for ongoing evaluations of Verzenio's efficacy.

Eli Lilly reported third-quarter 2021 revenues of $6.773 billion, an 18% increase from 2020, driven by a 35% rise in revenue from newer medicines. Net income was $1.110 billion, with reported EPS of $1.22, an 8% decline year-over-year. Non-GAAP EPS increased 38% to $1.94. The company announced several drug approvals and regulatory submissions, enhancing its growth potential. Lilly expects full-year revenue between $27.2 billion and $27.6 billion, reflecting strong performance in key products despite a projected decline in certain older therapies.

Eli Lilly's tirzepatide demonstrates significant efficacy in managing type 2 diabetes, showcasing superior reductions in A1C and body weight compared to insulin glargine in the SURPASS-4 trial. Over 52 weeks, the highest dose of tirzepatide resulted in a 2.58% A1C reduction and an 11.7 kg weight loss. Safety profiles remained consistent with gastrointestinal side effects being most common. The trial, involving 2,002 participants, confirmed tirzepatide's effectiveness and safety over 104 weeks, indicating promising long-term management for patients with increased cardiovascular risk.

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a fourth-quarter dividend of $0.85 per share on outstanding common stock. This dividend is scheduled for payment on December 10, 2021, to shareholders on record as of November 15, 2021. Eli Lilly continues its commitment to improving healthcare through innovative medicines while balancing business growth and shareholder returns.

Eli Lilly and Company (NYSE: LLY) has announced promising results from the Phase 3 monarchE trial for Verzenio® (abemaciclib) in treating high-risk early breast cancer. The study demonstrated a statistically significant improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) after a median follow-up of 27 months. At three years, IDFS improved by 5.4%, while DRFS improved by 4.2%. The data suggests that adding Verzenio to endocrine therapy could revolutionize treatment for patients at high risk of recurrence. Safety profiles remained consistent with known data.

Eli Lilly's Verzenio^® (abemaciclib) has received FDA approval for the adjuvant treatment of adult patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This marks it as the first CDK4/6 inhibitor approved for this indication. The approval stems from the positive results of the monarchE trial, demonstrating a statistically significant improvement in invasive disease-free survival (IDFS) among patients treated with Verzenio in combination with endocrine therapy.

Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2021 financial results on October 26, 2021. A conference call will follow at 9 a.m. Eastern time for discussing performance details with investors and media. The call will be accessible via webcast on Lilly's website, with a replay available afterwards. Established over a century ago, Lilly continues to focus on improving global health through innovative medicines and community engagement. For more information, visit www.lilly.com.

Loxo Oncology at Lilly has announced the preclinical characterization of two new cancer agents, LOXO-783 and LOXO-435, to be presented at the 2021 AACR-NCI-EORTC Virtual Conference. Both drugs are designed for specific cancer mutations, with LOXO-783 targeting PI3Kα H1047R mutations and LOXO-435 focusing on FGFR3. IND applications for both are planned in 2022. CEO Jacob Van Naarden emphasized their potential to enhance efficacy and tolerability compared to existing treatments.